Bakker Juliet Tammenoms
CIK 1431159 · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VERA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
800 EL CAMINO REAL, SUITE 220
MENLO PARK, CA 94025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RXST | Director | 86,731 | $4.80 | $416.3K | -$13.82M | 18 | 2026-06-18 |
| CBLL | Director | 2,498,394 | $26.96 | $67.36M | $4.03M | 3 | 2026-06-04 |
| VERA | 10%+ Owner | 3,429,927 | $30.25 | $103.76M | $60.00M | 1 | 2023-02-08 |
| Sierra Oncology, Inc. (SRRA) Delisted | 10%+ Owner | 175,000 | $54.99 | $9.62M | $28.35M | 3 | 2022-02-02 |
| RPID | 10%+ Owner | 150,000 | $0.70 | $105.4K | $18.00M | 1 | 2021-07-20 |
| Eargo, Inc. (EAR) Delisted | Director | 96,286 | $2.57 | $247.5K | $4.20M | 4 | 2021-05-19 |
| Tourmaline Bio, Inc. (TALS) Delisted | 10%+ Owner | 322,078 | $27.20 | $8.76M | $15.98M | 1 | 2021-05-11 |
| AXNX | Director | 783,533 | $1.00 | $783.5K | $7.51M | 9 | 2020-09-22 |
| Molecular Templates, Inc. (MTEM) Delisted | 10%+ Owner | 0 | $0.00 | $0 | $29.85M | 2 | 2020-09-01 |
| Venus Concept Inc. (HAIR) Delisted | Director | 231,772 | — | — | $0 | 1 | 2019-11-07 |
| Tricida, Inc. (TCDA) Delisted | 10%+ Owner | 3,019,734 | $0.11 | $326.1K | $10.00M | 1 | 2018-07-02 |
| Aptinyx Inc. (APTX) Delisted | 10%+ Owner | 3,190,079 | $0.06 | $194.6K | $7.20M | 1 | 2018-06-26 |
| COLL | 10%+ Owner | 6,029,785 | $23.68 | $142.79M | $12.30M | 2 | 2018-02-26 |
| CORT | Director | 10,874,259 | $80.46 | $874.94M | $11.70M | 4 | 2016-12-19 |
| Esperion Therapeutics, Inc. (ESPR) Delisted | 10%+ Owner | 1,883,769 | $3.18 | $5.99M | -$1.55M | 2 | 2014-10-14 |
Recent Filings · Page 5 of 6
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-12-05 | Molecular Templates, Inc. (MTEM) Delisted | Buy (P) | +3,750,000 | $30.00M | EDGAR |
| 2019-11-07 | Venus Concept Inc. (HAIR) Delisted | Grant (A) | +3,666,119 | $0 | EDGAR |
| 2019-08-26 | AXNX | Grant (A) | +5,000 | $0 | EDGAR |
| 2019-08-15 | AXNX | Grant (A) | — | $0 | EDGAR |
| 2019-07-01 | AXNX | Grant (A) | +1,667 | $0 | EDGAR |
| 2018-12-10 | AXNX | Grant (A) | +2,500 | $0 | EDGAR |
| 2018-11-02 | AXNX | Mixed | +2,933,333 | $8.00M | EDGAR |
| 2018-07-02 | Tricida, Inc. (TCDA) Delisted | Mixed | +12,078,936 | $10.00M | EDGAR |
| 2018-06-26 | Aptinyx Inc. (APTX) Delisted | Mixed | +9,570,237 | $7.20M | EDGAR |
| 2018-02-26 | COLL | Buy (P) | +9,375 | $300.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.